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Abstract 
Provision of social support and rehabilitation for patients with physical, mental and functional problems 
after cancer treatment is important for long-term health-related quality of life (HRQOL). Effective use of 
human and financial healthcare resources requires identification of patients requiring rehabilitation. The 
objectives of the current study were to clarify the patterns of physical and psychosocial recovery over 
time, to evaluate the associations among baseline variables, treatment-related factors and HRQOL at 6 
months, 1 and 2 years after breast cancer surgery, and to identify the significant factors predicting 
HRQOL at each point. A multicenter longitudinal study was performed to evaluate physical conditions, 
anxiety, depression and HRQOL at one month (baseline), 6 months, and 1 and 2 years after surgery in 196 
patients (mean age: 53.3 years old) with early breast cancer and no postoperative recurrence. Physical 
conditions were evaluated using a patient-reported symptom checklist. HRQOL was rated using the 
Functional Assessment of Cancer Treatment scale-General (FACT-G) and the Breast Cancer subscale 
(FACT-B). Anxiety and depression were rated using the Hospital Anxiety and Depression Scale (HADS). 
More than 50% of patients had local problems of "tightness", "arm weakness" and "arm lymphedema", 
and systemic problems of "reduced energy, fatigue, and general weakness" postoperatively. The HRQOL 
score significantly improved one year after surgery, and scores for physical, emotional and functional 
well-being also increased with time, whereas the score for social well-being was highest at baseline and 
decreased with time. Depression and anxiety significantly improved with time. Concomitant disease, 
marital status and the presence of a partner, anxiety and depression at baseline, pathological lymph node 
involvement, and adjuvant intravenous chemotherapy were significant factors predicting FACT-G scores 
at 6 months and 1 and 2 years after surgery. Depression at baseline was a strong predictor of HRQOL up 
to 2 years after surgery. These results suggest that physical rehabilitation is required for tightness and 
lymphedema to improve long-term postoperative physical function. A further study of psychosocial 
interventions is required to improve depression and social well-being after breast cancer surgery. 
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Introduction 
Data in the National Statistics of Cancer Registries by Region (1975-2004) indicate that the 
prevalence of breast cancer in Japan has increased continuously since 1975. More than 50,000 patients are 
thought to have breast cancer in 2004 and the mammary gland is the most common site of a malignant 
tumor in women [1]. Based on the Vital Statistics Japan database (Statistics and Information, Department, 
Ministry of Health, Labour and Welfare), the mortality of breast cancer has also increased, although this 
is still ranked fifth after lung, stomach, colon and pancreatic cancers. This suggests that breast cancer has 
a better prognosis than other solid cancers and that many patients overcome breast cancer. Cancer 
survivors in the United States have reached approximately 12 million and female patients with breast 
cancer accounted for 23% in 2006 [2]. 
Treatment for breast cancer has become increasingly complicated and includes surgery, radiotherapy, 
endocrine therapy, chemotherapy and targeted molecular treatment. These therapies are based on 
scientific evidence of survival benefits, but may have undesirable acute and chronic physical, functional, 
mental and social effects. Health-related quality of life (HRQOL) is a multidimensional, multifaceted 
concept that includes the influence of disease and treatment on the patient’s life, with QOL being an 
important outcome of cancer therapy [3, 4]. The improvement of overall HRQOL after surgery for breast 
cancer is generally dependent on the time from diagnosis to treatment [5]. However, breast cancer 
patients after diagnosis have poorer physical functioning in comparison with healthy controls [6- 9], and 
more frequent malaise [10-12]. Furthermore, breast cancer patients feel more stress and anxiety about the 
future compared to the general population and have lower mental domain scores [13-15]. These findings 
suggest that the diagnosis and various treatments of breast cancer will affect the long-term HRQOL. 
Cancer survivorship research seeks to identify, examine, prevent and control adverse cancer- and 
treatment-related outcomes. The most important task is to provide a social support system and 
rehabilitation for patients with long-term physical, mental and functional problems after cancer treatment, 
with the goal of improving long-term HRQOL, on which social support has a great effect [5, 8, 14, 16]. 
To distribute limited human and financial healthcare resources more effectively, it is important to 
understand HRQOL of breast cancer patients comprehensively. This includes clarifying patterns of 
physical and psychosocial recovery over time, identifying social backgrounds, clinicopathological and 
treatment-related factors that influence long-term HRQOL, and identifying areas and persons requiring 
support in the future.  Factors with significant effects on long-term HRQOL after treatment of breast 
cancer include age [18- 25], race [9, 25], educational status [19- 21], income [7, 8, 13], marriage [11, 13, 
21, 24, 25], recurrence [9, 26], disease period [11, 20], surgical procedure [7, 19, 20], chemotherapy [8, 
10, 11, 14, 20, 24], physical activities [27] and culture [25, 28]. In our previous longitudinal prospective 
study, the factors predicting HRQOL at one year after surgery were mood disturbance, poor body image, 
lower income and positive axillary nodes one month after surgery [17]. 
As described above, the improvement of overall HRQOL after surgery for breast cancer is generally 
dependent on the time from diagnosis to treatment, so evaluation at this point is very important when 
assessing HRQOL [8, 22, 23]. Social and clinicopathological factors that have significant effects on 
HRQOL may differ at different time points, and therefore accurate evaluation of HRQOL requires 
prospective studies. Many previous studies were cross-sectional, while few longitudinal prospective 
studies have been performed [8, 11, 14, 17-20, 26, 27]. 
The objectives of the current study were to clarify the patterns of physical and psychosocial recovery 
over time, to evaluate the associations among baseline variables, treatment-related factors and HRQOL at 
6 months, 1 and 2 years after breast cancer surgery, and to identify the significant factors predicting 
HRQOL at each time point by prospectively determining HRQOL. 
 
Patients and Methods 
Study design 
The study was designed based on the hypothesis that psychological distress, body image, lower 
income, and positive axillary nodes one month after surgery for breast cancer are important predictors of 
postoperative HRQOL in Japanese women. This hypothesis was developed from the results of our earlier 
study [17]. The current analysis was conducted as a multicenter longitudinal study. The subjects were 
patients with primary breast cancer who underwent breast surgery and their data of the surgical procedure, 
area of lymph node dissection, and lymph node metastases were available. All subjects gave written 
informed consent for participation in the study. The exclusion criteria were lymph node involvement of 
N2 or more in preoperative UICC TNM classification, preoperative therapy (including chemotherapy, 
endocrine therapy, radiotherapy), bilateral breast cancer, double cancer, cancer in pregnancy or the 
lactating period, and male breast cancer. Patients who met the inclusion criteria at less than 6 weeks after 
surgery for breast cancer were recruited. After registration, physical symptoms, anxiety and depression, 
and HRQOL (see below) were evaluated at baseline and 6 months and 1 and 2 years after surgery. 
Patients in whom recurrence was confirmed during the follow-up period discontinued the study. A total of 
8 institutions in Japan participated in the study: Kawasaki Medical School Hospital, Shikoku Cancer 
Center, Showa University Toyosu Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center 
Komagome Hospital, Kurashiki Medical Center, Cancer Institute Hospital of the Japanese Foundation for 
Cancer Research, National Cancer Center Hospital, and Fukushima Medical University Hospital. 
 
Data collection 
Information on marital and educational status, occupation, income and family was obtained from a 
baseline questionnaire. Information on the following clinicopathological and therapeutic factors was 
obtained from medical records: surgical procedures (mastectomy or breast-conserving surgery (BCS)), 
clinical stage, pathological stage, radiotherapy, performance status, postoperative chemotherapy and 
chemotherapeutic agents used, postoperative endocrine therapy and agents used, recurrence, and 
concomitant disease. 
 
Health-related quality of life instruments 
HRQOL was assessed at one (baseline), 6, 12 and 24 months after breast cancer surgery using the 
Japanese version of the Functional Assessment of Cancer Treatment Scale-General (FACT-G) and the 
Breast Cancer subscale (FACT-B). The questionnaires were returned by mail. The FACT-G was 
developed by Cella et al. in 1993 to evaluate HRQOL of patients with chronic disease and has been 
widely used [29]. The FACT-G version 4 consists of 27 items: 7 in the physical subscale, 7 in the social 
and family subscale, 6 in the mental subscale, and 7 in the functional subscale. The FACT-B is a breast 
cancer-specific HRQOL questionnaire consisting of FACT-G and an additional 9 items in the breast 
subscale [30]. Higher scores indicate better HRQOL. The reliability and validity of the Japanese version 
of the FACT-G and FACT-B have been verified [31-33]. 
 
Instrument for psychosocial distress 
The Hospital Anxiety and Depression Scale (HADS) was used to detect clinically significant anxiety 
and depression. The study period was the same as that of the HRQOL survey. The HADS is a 14-item 
self-rating scale [34-37] on which each item is rated on a scale of 1 to 4. Higher scores indicate a greater 
tendency for anxiety and depression. The validity and reliability of the Japanese version of HADS have 
been shown [38]. 
 
Patient-reported symptom check list 
Physical problems related to disease and treatment were evaluated using a patient-reported symptom 
checklist. In our previous study, we developed a list of symptoms related to disease and treatment and 
collected these data in a structured interview [17]. In the current study, this list was translated into 
Japanese and the patient-reported symptom checklist was developed. The checklist included 2 questions 
on body image, 11 on local postoperative problems, 2 on activities of daily living, 4 on systemic 
symptoms including fatigue, and 10 on physical activity, pain, weight and diet, acute post-surgical 
complications, radiotherapy, chemotherapy and endocrine therapy, recreation and social activities; i.e., 29 
questions in total. The questionnaire uses a 5-point Likert scale of 0: not at all, 1: a little bit, 2: somewhat, 
3: quite a lot, and 4: very much; in accordance with the FACT. 
 
Statistical analysis 
Changes in overall HRQOL; in physical, psychological, functional and social well-being domains, 
and corresponding facets; and in predictors of long-term HRQOL were evaluated in the study. Multiple 
regression analysis was performed to examine baseline variables that were predictive of HRQOL outcome 
(FACT-G, Breast Cancer subscale and FACT-B Trial Outcome Index) after 6 months and 1 and 2 years. 
The FACT-B Trial Outcome Index (TOI) is the sum of scores from the physical and functional well-being 
and the Breast Cancer subscale. The 23 items have a maximum sum of 92, reflecting a good HRQOL. 
The following baseline variables (data at one month after surgery) were used as independent predictors: 
demographic and medical characteristics (age [≤49, 50-69, ≥70 years old], marital status [married or with 
a partner / single or without a partner due to divorce or bereavement], children [presence / absence of 
children], education [junior or high school / university or higher], employment status [full-time or 
part-time job / housewife or jobless], household income [annual income < 5 million Japanese Yen (JPY) / 
5 - 10 million JPY / > 10 million JPY], concomitant disease [history of hypertension, diabetes, 
hyperlipidemia, or other diseases / no medical history], pathological nodal involvement [pathological 
lymph node involvement / no involvement], and surgical procedure [BCS / mastectomy]). The income 
classification used in the analysis was established using almost the same amounts as those in previous 
studies, based on the exchange rate at that time. Mental depression was included in the analysis model as 
a continuous variable using the HADS score for Depression and Anxiety determined at baseline. Body 
image was evaluated using 2 questions in the symptom checklist ("I am displeased with my change in 
body shape." and "I hesitate to show my body to others.") and the results were included in the model as an 
ordinal variable with 5 grades from 0 to 4. It has also recently been shown that adjuvant therapy including 
radiotherapy, hormone therapy and chemotherapy after surgery for breast cancer has effects on HRQOL. 
Therefore, postoperative treatment-related factors were added as potential predictive factors. 
Postoperative radiotherapy [radiation administered to the remaining breast or chest wall / no radiation], 
chemotherapy [intravenous chemotherapy / chemotherapy with oral 5-FU / no chemotherapy], and 
endocrine therapy [endocrine therapy / no endocrine therapy] were also added to the analysis model. 
Multiple regression analysis was conducted by the least squares method using FACT-G, Breast Cancer 
subscale and FACT-B TOI scores as objective variables and the baseline and treatment-related factors 
described above. Differences were considered to be significant at the 5% level and the contribution ratio 




Demographic and clinical characteristics of the subjects 
The subjects were recruited in 8 institutions in Japan from December 1998 to March 2003 and consent 
for participation in the study was obtained from 196 patients. The demographic and clinical 
characteristics of the subjects at one month after surgery are shown in Table 1. The mean age of the 
subjects was 53.3 years old. Most patients were married (70.9%) and about 28% had a college education. 
About 50% of the subjects underwent BCS, which is consistent with the general population of Japanese 
breast cancer patients. Sentinel lymph node biopsy was not generally conducted in Japan from 1998 to 
2003, so radical dissection of axillary lymph nodes of level I or more was conducted in all patients. 
Pathological lymph node involvement was found in 34.7% of the subjects.  
Of 97 patients who underwent BCS, 82 (84.5%) underwent radiotherapy for the remaining breast. 
Post-mastectomy irradiation was conducted in 2 (2%) of 99 patients who underwent mastectomy. 
Postoperative adjuvant chemotherapy was conducted in 112 of 196 patients. The major regimens were 
cyclophosphamide, methotrexate and fluorouracil (CMF) in 66 patients (59%), and 
anthracycline-containing regimens in 19 (17%). Docetaxel monotherapy was administered to 2 patients, 
and oral 5FU such as uracil and ftorafur (UFT) was given to 25 patients. Postoperative hormone therapy 
was administered in 126 patients (64.3%) using tamoxifen in 102 (81%), toremifene in 7, anastrozole in 1, 
and a combination of tamoxifen and gonadotropin-releasing hormone analogs in 16. During the 2-year 
follow-up period, there was recurrence in 12 patients (6.1%): in 3, 1 and 8 within 6 months, 1 year and 2 
years, respectively. The recurrent organs were the local site and a lymph node close to the lesion in 6 
cases; and bone, lung and liver metastases in 2, 1 and 3, respectively. No patient died during the 
follow-up period. 
 
Physical and treatment-related problems 
The response rates for the patient-reported symptom checklist were 97.4%, 96.4%, 94.9% and 79.6% 
at registration, and at 6 months and 1 and 2 years, respectively. Physical and treatment-related problems at 
1 month and 1 and 2 years after surgery are shown in Table 2. Most of these problems gradually 
decreased with time. However, more than 50% of patients complained of at least one of the following 
problems at 2 years after surgery: “tightness or tenderness in the chest wall” in mastectomy; “tightness, 
tenderness or discomfort in the breast” in BCS; “arm weakness” in BCS; “arm lymphedema” in BCS; 
“sensory loss (chest wall, axilla, or arm)”, “tightness, pulling or stretching (arm or axilla)”; “reduced 
energy, fatigue, general weakness” in mastectomy and BCS; and “intermittent pain or mild pain” in BCS. 
The percentage and severity of these symptoms remitted with time, but those for “cognitive difficulties”,  
“weight gain, including difficulty in losing weight” and “endocrine problems” increased over time and 
half or more of the subjects complained of these symptoms. 
 
Changes in HRQOL scores 
The response rates for the questionnaire were 97%, 96%, 93.4% and 86.7% at registration, and at 6 
months and 1 and 2 years, respectively. The mean, standard deviation and alpha coefficient of the scores 
for each domain, TOI, FACT-G and FACT-B at baseline, and 6 months and 1 and 2 years after surgery are 
shown in Table 3. The scores for physical, emotional and functional well-being increased with time 
(better HRQOL). The score for functional well-being at 6 months after surgery and emotional well-being 
at 1 year after surgery were significantly higher than those at baseline. In contrast, the score for social 
well-being was highest at baseline and then decreased with time and was significantly lower at 6 months 
and thereafter compared with baseline. The scores for the Breast Cancer subscale did not change 
significantly. The TOI, FACT-G and FACT-B scores increased with time (improved HRQOL) and showed 
a significant improvement at 1 and 2 years after surgery compared with baseline. After 2 years, the mean 
TOI, FACT-G and FACT-B scores were improved by 7.5, 4.8 and 4.9 points, respectively, compared to 
the baseline scores. Alpha coefficients ranged from 0.71 to 0.9, except for the Breast Cancer subscale 
(0.51-0.53).  
 
Changes in HADS scores 
The mean, standard deviation and alpha coefficient of the HADS scores at baseline, and 6 months and 
1 and 2 years after surgery are shown in Table 4. In general, HADS depression, anxiety and total scores 
decreased with time (less depression and anxiety). The scores for HADS depression showed a significant 
improvement at 1 and 2 years after surgery in comparison with baseline, but the scores for HADS anxiety 
did not change significantly. The scores for HADS total showed a significant improvement at 2 years after 
surgery in comparison with baseline, and the mean HADS score decreased from 10.4 points to 9.1 points. 
Alpha coefficients for the HADS scores ranged from 0.73 to 0.89. 
 
Associations among baseline variables, treatment-related factors and HRQOL at 6 months, 1 and 2 years 
after breast cancer surgery 
   We next examined the relationship between potential predictor variables and HRQOL outcome at 6 
months and 1 and 2 years after surgery, using multiple regression analysis of Breast Cancer subscale, 
FACT-B TOI and FACT-G scores. The results are shown in Table 5. The variables with a significant 
effect on the Breast Cancer subscale score were employment status, poor body image, anxiety, depression, 
age, chemotherapy, endocrine therapy, type of surgery. Poor body image at baseline was a significant 
predictive factor for the Breast Cancer subscale score, with patients with a poor body image at 1 month 
after surgery having a low Breast Cancer subscale score (worse HRQOL) at 6 months and 2 years after 
surgery. HADS anxiety score and age were significant predictive factors for Breast Cancer subscale 
scores at 6 months and 1 year after surgery. HADS depression and chemotherapy had a particularly 
important effect and these variables were significant predictors for Breast Cancer subscale scores at 6 
months and 1 and 2 years after surgery. Patients with a higher HADS depression score (more depression) 
and those treated with adjuvant intravenous chemotherapy had a lower Breast Cancer subscale score 
(worse HRQOL). The variables with a significant effect on the FACT-B TOI score were concomitant 
disease, children, poor body image, anxiety, depression, age, positive lymph node involvement, 
chemotherapy, type of surgery. HADS depression and chemotherapy also had a particularly important 
effect and were significant predictors for FACT-B TOI scores at 6 months and 1 and 2 years after surgery. 
   Concomitant disease was a significant predictive factor for the FACT-G scores at 6 months and 1 year 
after surgery, with patients with concomitant hypertension, hyperlipidemia or diabetes having low 
FACT-G scores (worse HRQOL). The HADS anxiety score at baseline was a significant predictive factor 
for the FACT-G scores at 6 months and 1 year after surgery. The HADS depression score at baseline was 
also a significant predictive factor for the FACT-G scores at 6 months and 1 and 2 years after surgery. The 
depression score had a particularly important effect and was the strongest parameter in the model. 
Pathological lymph node involvement and adjuvant intravenous chemotherapy were significant predictive 
factors at 6 months and 2 years after surgery, with patients with pathological lymph node involvement 
having a higher HRQOL score (better HRQOL) and those treated with adjuvant intravenous 
chemotherapy having a lower HRQOL score (worse HRQOL). Marital status or the presence of a partner 
at surgery was a significant predictive factor for the FACT-G score at 2 years after surgery, with this score 
being higher in patients with a partner.  
   In general, significant factors affecting the Breast Cancer subscale, FACT-B, TOI and FACT-G scores 
differed at each assessment point, but the HADS depression score at baseline and adjuvant intravenous 
chemotherapy were consistent significant factors affecting all examined HRQOL scores at almost all 
assessment points within 2 years after breast cancer surgery. 
 
Discussion 
In this study, physical problems related to disease and treatment were evaluated using a 
patient-reported symptom checklist. Many patients complained of such physical problems even 2 years 
after surgery. Most physical symptoms remitted with time, but local symptoms such as “tightness, 
tenderness in the breast or chest wall", "sensory loss (chest wall, axilla, or arm)" and "tightness, pulling or 
stretching (arm or axilla)" were perceived by more than half of the patients at 2 years after surgery. 
Furthermore, the systemic symptoms of "reduced energy, fatigue, general weakness" were perceived by 
more than 60% of the patients at 2 years after surgery. The improvement in most symptoms with time and 
the persistence of tightness and sensory loss and reduced energy, fatigue and general weakness were 
consistent with our previous study [17]. 
The frequency of arm lymphedema increased with time and the incidence at 2 years after surgery was 
more than 50% in patients who underwent BCS. The symptom of "sensory loss" is thought to be caused 
by breakage or damage of nerves in surgery and was similar in patients who received mastectomy and 
BCS. There is no effective treatment to improve long-term sensory loss; therefore, it is necessary to 
explain to patients prior to surgery that there is a strong risk of sensory loss, and that if sensory loss 
occurs it is difficult to improve and may remain for a long time. Conservation of the intercostobrachial 
nerve (ICBN) in axillary lymph node dissection (ALND) improves long-term sensory deficits in the upper 
arm without influencing survival [39]. The symptoms of tightness and arm lymphedema perceived in the 
remaining breast, chest wall, arm and axilla are likely to be caused by ALND, postoperative contracture 
and radiotherapy. A recent prospective cohort study of upper limb dysfunction (ULD) after surgery for 
breast cancer determined the incidence, time course and risk factors for various ULD subtypes, including 
pectoralis tightness, lymphedema and lymphostasia, myofascial pain syndrome, rotator cuff disease, 
adhesive capsulitis, and post-mastectomy pain syndrome [40]. The highest incidences of ULD were due 
to pectoralis tightness and lymphedema, which is consistent with our results, and development of these 
symptoms caused long-term rotator cuff disease, indicating that physical rehabilitation is needed in 
patients with tightness and lymphedema to improve long-term postoperative physical function.  
Generalization of the information on local symptoms after breast surgery found in this study is limited 
because sentinel lymph node biopsy (SLNB) is currently covered by National Health Insurance and is 
generally conducted in patients with clinical node-negative results, which differs from the conditions at 
the time the study was conducted. Widespread SLNB has decreased the frequency of ALND, and patients 
show significantly less treatment-related upper limb morbidity after SLNB compared with ALND [41]. 
The symptom of "weight gain, including difficulty in losing weight" increased with time, in contrast to 
general physical symptoms, which was also consistent with our previous study [17]. Negative 
associations between excessive body weight and breast cancer recurrence and survival have been reported 
in pre- and postmenopausal women [42], and the American Cancer Society recommends that patients 
with cancer maintain normal weight as a potential aid in prognosis [43]. The results of this study showed 
that breast cancer patients recognized the importance of body weight control, but struggled to control 
body weight. These results show that it is necessary not only to keep patients informed about body weight 
control after surgery, but also to build a comprehensive support system for improving lifestyle, including 
exercise and diet to control body weight. 
The results of our previous study showed that the incidence of "cognitive difficulties" decreased with 
time. In contrast, this incidence increased with time in the current study and more than half of the patients 
complained of this symptom at 2 years after surgery. However, no objective cognitive function was 
evaluated in the study and this limits discussion of these results. There has been a recent focus on the 
effect of adjuvant therapy after surgery for breast cancer on cognitive function, including memory, 
attention and executive function. However, it remains unclear whether postoperative chemotherapy has an 
effect on cognitive function since different results have been found. Adjuvant CMF chemotherapy caused 
late cognitive impairment [44] and subjects treated with high-dose chemotherapy with cyclophosphamide, 
thiotepa and carboplatin showed a decline in cognitive performance compared with healthy controls [45]; 
however, it has also been found that postoperative chemotherapy had almost no effect on cognitive 
function [46]. The tendency seems to be that subjective ratings of memory and concentration decrease 
after treatment with chemotherapy, and that breast cancer patients treated with chemotherapy also seem to 
be more likely than controls to perceive themselves as impaired [47]. It is also unclear whether tamoxifen 
used for postoperative endocrine therapy has an effect on cognitive function [48, 49], and the effect of 
aromatase inhibitors, the first option for postmenopausal breast cancer, on cognitive function is also an 
important issue for further study [50, 51]. 
HRQOL after surgery for breast cancer improved over time based on the increase in mean TOI, 
FACT-G and FACT-B scores. Physical, emotional and functional well-being significantly improved, but 
social well-being significantly decreased. Lu et al. [20] recently examined changes in HRQOL and factors 
predicting long-term HRQOL in breast cancer patients using an approach similar to that in the current 
study. HRQOL was evaluated in 2232 Chinese patients with breast cancer who enrolled in the Shanghai 
Breast Cancer Survival Study at 6 and 36 months after diagnosis. Overall HRQOL and physical, 
psychological and social well-being improved over time, while several factors showed a decline with time, 
including negative feelings, social support, interpersonal relationships, financial situation and living 
environment, with a particularly marked worsening of interpersonal relationships [20]. The FACT-G 
questions concerning social well-being examine relationships with family, partner and friends; therefore, 
the decreased social well-being found in the current study is similar to the changes observed by Lu et al. 
Bloom et al. found that emotional support and the size of a patient's social network, which were included 
in the domain related to social well-being, significantly decreased at 5 years after surgery in a longitudinal 
study in breast cancer patients aged 50 years old or less [14]. These results suggest that support for cancer 
survivors requires maintenance and improvement of social well-being after treatment, and that 
psychosocial support is necessary for maintenance of good relationships with family, partner and friends. 
In a long-term follow up study, Ganz et al. found that physical and emotional well-being decreased in 
comparison with baseline in disease-free breast cancer survivors over a mean period of 6.3 years after 
early treatment, but that the changes were not significant when the effect of aging was included [8]. Ganz 
et al. also found that there was no significant change in energy levels or social functioning [8]. A 
comparison of changes in HRQOL based on differences in race and culture requires further accumulation 
of HRQOL data over a longer period. 
Our results allowed a clear conclusion to be drawn on factors predicting HRQOL after surgery for 
breast cancer. The HADS score at baseline (1 month after surgery), and especially the depression score, 
was the strongest significant predictor for HRQOL at 6 months and 1 and 2 years after surgery. Our 
previous study also showed a significant relationship between mood disturbance at 1 month after surgery 
and HRQOL at 1 year after surgery [17]. Thus, depression in the early period after surgery seems to be an 
extremely important factor determining postoperative long-term HRQOL regardless of race or culture. 
Therefore, important future issues include analysis of data from screening for depression in the early 
period after surgery and investigation of the effects of interventions such as mental rehabilitation on 
depression and overall HRQOL. There are only a few studies evaluating psychosocial interventions as 
breast cancer rehabilitation programs; however, psychoeducation, cognitive behavioral therapy and social 
and emotional support may be beneficial for improving QOL [52]. 
 Body image was a significant factor associated with HRQOL in our previous study. It has been 
suggested that traditionally the breast carries less significance in sexuality and body image in Asian 
cultures than in Western countries, and that attitudes on changes in body image caused by breast cancer 
treatment depend on race and social background [20]. The results of this study in Japanese women 
showed that body image at baseline had no significant effect on the FACT-G, a comprehensive QOL scale. 
However, body image had significant effects on Breast Cancer subscales and FACT-B TOI, including 
femininity and physical and functional factors. Therefore, breast cancer in Japanese patients should be 
treated with consideration of body image. 
Income was also a significant factor in our previous study, but was not significant in this study. In our 
previous study, the income of patients was classified into 3 categories with cut-off values of 30,000 and 
60,000 dollars to provide factors for analysis. The dollar-yen exchange rate was approximately 150 yen in 
1987 when our previous study began; therefore, the cut-off values were approximately 4.5 and 9 million 
yen (http://research.stlouisfed.org/fred2/data/EXJPUS.txt). These values are close to the cut-off values in 
this study (5 and 10 million yen). All previous studies that indicated a significant correlation between 
income and HRQOL were conducted in the United States [7, 8, 13, 17]. The difference in the results in 
this study may be due to the difference in the health insurance system in Japan.  
Pathological lymph node involvement also had an unusual effect, since it was related to high HRQOL 
scores at 6 months and 2 years after surgery. This finding requires further analysis, since cancer 
progression generally correlates with poor HRQOL [11, 20]. Of the treatment-related factors, intravenous 
systemic chemotherapy after surgery was the strongest significant predictor for HRQOL. We also note 
that Ganz et al. found that systemic pharmacotherapy after surgery was significantly associated with 
physical function at 5-10 years after diagnosis [8]. Therefore, it is important for physicians to recognize 
that postoperative systemic chemotherapy has a long-term effect on HRQOL, even after completion of 
treatment. Further cancer survivorship studies should be conducted to investigate the kinds of support 
needed to improve long-term HRQOL in breast cancer patients who are treated with chemotherapy. The 
results of symptom checklists of therapy-related factors showed that hot flash and other symptoms 
associated with endocrine therapy showed a time-dependent increase. On the other hand, endocrine 
therapy itself had less effect on overall HRQOL and even had a positive effect on breast cancer subscales 
one year after therapy. Adjuvant endocrine therapy reduces the risk of breast cancer recurrence and death. 
Endocrine therapy is beneficial for patients with hormone receptor-positive breast cancer. 
In conclusion, patients with breast cancer have physical symptoms for a long period postoperatively. 
Our results suggest that physical rehabilitation should be performed in patients with tightness and 
lymphedema to improve long-term postoperative physical function. Patients should be supported with a 
comprehensive system for improving lifestyle after surgery, including exercise and diet to control body 
weight, because they recognized the importance of body weight control, but struggled to control body 
weight. HRQOL and anxiety/depression generally improved with time after surgery, but depression in the 
early period after surgery has a major effect on long-term HRQOL, and the score for social well-being 
decreased with time. Therefore, further studies are required to examine depression with a screening tool 
and psychosocial support as part of breast cancer rehabilitation. 
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Table 1. Demographic and medical characteristics of the sample (N=196)
Age at baseline, years Clinical stage at diagnosis
    Mean     0 11 5.6
    Range    Ⅰ 72 36.7
   Ⅱ 102 52.0
Age group at baseline, years    ⅢA 9 4.6
    <50 75 38.3    ⅢB 2 1.0
    50-69 106 54.1
    70 and older 15 7.7 Pathological nodal involvement
    Negative 128 65.3
Marital status     Positive 68 34.7
    Single 22 11.2
    Married 139 70.9 Surgical procedure
    Separated 1 0.5     Breast conserving surgery 95 48.5
    Divorced 9 4.6     Modified Radical mastectomy 94 48.0
    Widowed 20 10.2     BCS* and reconstruction 2 1.0
    Unknown 5 2.6     Mastectomy and reconstruction 5 2.6
Education
    High school or less 135 68.9 Received adjuvant radiotherapy
    College education 54 27.6     No 112 57.1
    Unknown 7 3.6     Yes 84 42.9
Employment status before diagnosis Received adjuvant chemotherapy
    Not working 107 54.6     No 84 42.9
    Working 68 34.7     Yes 112 57.1
    Unknown 21 10.7
Received adjuvant endocrine therapy
Household income (Japanese Yen)     No 70 35.7
    -5,000,000 67 34.2     Yes 126 64.3
    5,000,000- 10,000,000 84 42.9
    10,000,000- 21 10.7 Recurrence
    Unknown 24 12.2     No 184 93.9
    Yes 12 6.1
Concomitant disease
    None 121 61.7
    Hypertension 25 12.8
    Hyperlipidemia 4 2.0
    Others 16 8.2




Characteristics Number %Characteristics Number %




    Difficulty in lifting 83.0 (24.5) 34.4 (2.2) 19.5 (1.3) 88.3 (20.2) 38.5 (3.3) 28.2 (3.8)
    Limited arm mobility or frozen shoulder 67.7 (15.1) 32.2 (4.4) 23.3 (0) 73.1 (14.0) 40.0 (6.8) 29.9 (3.9)
    Tightness, and/or tenderness in chest wall (mastectomy) 93.3 (33.8) 69.0 (14.3) 58.7 (10.7)
    Tightness, tenderness or discomfort in breast (BCS) 89.7 (27.6) 80.7 (19.3) 79.7 (17.4)
    Sensation that breast is still present (mastectomy) 45.5 (13.6) 34.1 (7.3) 35.6 (6.8)
        (phantom breast syndrome)
    Arm weakness 66.7 (9.7) 47.7 (6.7) 39.2 (5.4) 71.6 (18.2) 51.2 (4.9) 56.1 (6.8)
    Lymphedema of arm 27.2 (1.1) 26.1 (3.4) 33.3 (9.7) 41.2 (7.1) 47.6 (10.7) 52.1 (15.1)
    Swelling (chest wall, breast, and/or axilla) 60.4 (14.3) 31.1 (5.6) 33.8 (4.1) 71.6 (20.5) 59.0 (7.2) 40.3 (5.6)
    Numbness (chest wall, axilla, and/or arm) 61.3 (10.8) 48.8 (11.1) 36.5 (5.4) 75.3 (19.1) 53.6 (6.0) 47.9 (10.0)
    Sensory loss (chest wall, axilla, and/or arm) 93.5 (35.9) 87.4 (20.7) 73.0 (20.3) 85.9 (30.6) 85.7 (15.5) 83.6 (26.0)
    Tightness, pulling and/or stretching (arm and/or axilla) 96.8 (50.5) 85.6 (18.9) 59.5 (8.1) 91.0 (46.1) 74.1 (12.9) 70.3 (16.2)
Activity of daily living
    Difficulty in doing household chores 61.1 (4.2) 27.7 (4.4) 18.2 (1.3) 63.8 (12.8) 33.0 (1.1) 20.8 (2.6)
    Difficulty with self-care and grooming 55.8 (4.2) 16.3 (0) 10.4 (0) 62.8 (8.5) 12.1 (1.1) 14.3 (3.9)
Symptoms
    Less energy than before, fatigue, general weakness 82.1 (13.7) 70.3 (14.3) 68.4 (14.5) 83.2 (18.9) 71.4 (19.8) 66.7 (21.8)
    Cognitive difficulties 47.9 (4.3) 57.8 (12.2) 57.1 (16.9) 46.8 (7.5) 50.0 (12.2) 52.0 (18.2)
    Difficulty in sleeping 56.8 (12.6) 38.9 (14.4) 44.2 (9.1) 54.7 (12.6) 52.2 (6.7) 44.2 (16.9)
    Fatigue associated with treatments 41.3 (4.3) 8.9 (1.1) 13.2 (2.6) 43.6 (6.4) 18.0 (1.1) 15.6 (3.9)
Physical activities
    Difficulty in doing physical activities 72.9 (18.8) 41.1 (4.4) 33.8 (6.5) 75.8 (18.9) 39.1 (4.3) 30.8 (5.1)
Pain
    Intermittent pain or mild pain 75.0 (17.7) 59.8 (12.0) 41.6 (7.8) 82.1 (20.0) 63.0 (6.5) 56.4 (5.1)
Weight and diet
    Weight gain problem, including difficulty in losing weight 38.5 (3.1) 57.6 (13.0) 58.6 (18.7) 44.7 (4.3) 70.3 (22.0) 78.2 (28.2)
Endocrine problemsc
    Hot flashes from endocrine therapy or chemotherapy 27.0 (0) 41.7 (18.8) 45.2 (19.0) 26.3 (15.8) 57.3 (19.7) 55.9 (22.0)
    Other side effect from endocrine therapy 23.1 (11.5) 44.9 (18.4) 41.0 (20.5) 42.1 (5.3) 58.7 (12.7) 63.6 (16.4)
Recreational and social activities
    Decline in recreational and social activities 80.2 (41.8) 50.5 (15.4) 43.2 (10.8) 69.9 (22.6) 54.4 (11.1) 40.3 (9.1)
    Difficulty in planning activities 70.7 (27.1) 34.8 (4.5) 32.4 (2.8) 80.9 (22.3) 40.4 (5.6) 31.6 (6.6)
a: 5-point Likert scale (scale: 0 to 4) and % of the total excluding "0: Not at all"
b: 5-point Likert scale (scale: 0 to 4) and % of the total of "3: Quite a lot" and "4: Very much"
c: Denominator includes only subjects receiving endocrine therapy (N=126)
Percentages that are bolded were reported by >50% of women at two year
1Month 1Year 2Year
Mastectomy (N=99) Breast conserving surgery (N=97)
1Month 1Year 2Year
79
97.0 93.9 77.8 97.9 95.9 81.4
96 93 77 95 93
- - -
Problem Percentage of responders have any problems
a
(Percentage of responders have severe problemsb)
- - -
- - -
Table 3. Change of health-related quality of life score after breast cancer surgery
Mean SD alpha Mean SD alpha p Mean SD alpha p Mean SD alpha p
Quality of life assessment
       Physical well-being 21.0 4.6 0.78 21.6 5.4 0.85 0.221 24.3 3.8 0.78 <.0001 24.7 4.3 0.85 <.0001
       Social well-being 20.8 5.2 0.71 18.4 6.3 0.78 <.0001 17.7 6.7 0.83 <.0001 17.5 6.9 0.84 <.0001
       Emotional well-being 16.5 5.5 0.86 17.2 5.0 0.84 0.122 18.1 4.4 0.78 0.001 18.0 4.8 0.78 0.004
       Functional well-being 17.5 5.7 0.82 19.7 5.3 0.85 <.0001 20.9 5.6 0.88 <.0001 21.0 5.5 0.87 <.0001
       Breast cancer subscale 23.2 5.1 0.58 22.6 5.5 0.62 0.283 24.0 4.8 0.54 0.158 23.6 5.2 0.57 0.516
   Trial outcome indexa 62.0 12.1 0.85 64.0 12.9 0.86 0.122 69.2 11.2 0.85 <.0001 69.5 11.2 0.85 <.0001
    FACT-Gb 76.0 15.1 0.88 77.0 15.5 0.89 0.532 81.3 14.2 0.88 0.001 81.3 14.4 0.87 0.001
    FACT-Bb 99.5 18.1 0.89 99.6 19.2 0.90 0.952 105.1 17.2 0.88 0.004 105.0 17.2 0.87 0.006
a: Trial outcome index is the sum of the score from the physical and functional well-being and the breast cancer subscale
b: Functional assessment of cancer treatment scale- general and breast cancer subscale
The difference between the mean at each time point and baseline was analyzed using a paired t-test.
Baseline 6 months 1 year 2 years
(N=190) (N=188) (N=183) (N=170)
Table 4. Change of HADS score after breast cancer surgery
Mean SD alpha Mean SD alpha p Mean SD alpha p Mean SD alpha p
HADSa
       Depression 4.6 3.0 0.73 4.4 3.2 0.79 0.595 3.9 3.0 0.80 0.034 3.7 3.2 0.81 0.013
       Anxiety 5.8 3.3 0.80 5.6 3.2 0.78 0.607 5.4 3.2 0.80 0.256 5.4 3.7 0.83 0.244
    HADS-Total 10.4 5.7 0.86 10.0 5.9 0.86 0.569 9.3 5.7 0.870 0.079 9.1 6.4 0.89 0.050
a: Hospital anxiety and depression scale 
The difference between the mean at each time point and baseline was analyzed using a paired t-test.
Baseline 6 months 1 year 2 years
(N=190) (N=188) (N=183) (N=170)















    Employment status (housewife or jobless)a 0.69 0.38 0.068 1.03 0.38 0.007 0.22 0.42 0.611
    Poor body imagea -1.71 0.84 0.044 -1.00 0.84 0.234 -2.38 0.94 0.012
    Anxietyb -3.18 1.30 0.016 -2.85 1.33 0.035 -1.54 1.54 0.320
    Depressionb -2.81 1.06 0.009 -2.84 1.06 0.009 -2.81 1.20 0.021
    Age (≤49)a 1.91 0.80 0.018 2.42 0.80 0.003 1.45 0.89 0.108
    Adjuvant intravenous chemotherapy -3.81 0.51 <.0001 -1.84 0.51 <.0001 -1.83 0.56 0.002
    Adjuvant endocrine therapy 0.68 0.38 0.079 0.81 0.39 0.037 0.18 0.43 0.680
    Breast conserving surgery -1.23 0.67 0.068 -0.12 0.65 0.853 -1.53 0.74 0.040
Trial outcome index
    Concomitant diseasec -2.03 0.92 0.030 -2.75 0.90 0.003 -1.12 1.00 0.265
    Children (presence)a -1.72 0.85 0.046 -1.30 0.83 0.118 -0.35 0.89 0.690
    Poor body imagea -0.52 1.94 0.790 -1.13 1.90 0.554 -4.41 1.99 0.029
    Anxietyb -6.01 3.03 0.049 -5.81 3.02 0.057 -1.20 3.30 0.718
    Depressionb -9.53 2.42 <.0001 -9.96 2.39 <.0001 -9.00 2.54 0.001
    Positive lymphnode involvement 1.56 0.95 0.103 1.63 0.94 0.087 2.79 1.00 0.006
    Adjuvant intravenous chemotherapy -8.58 1.17 <.0001 -2.46 1.19 0.041 -4.52 1.19 <.0001
    Breast conserving surgery -2.14 1.54 0.167 -0.11 1.46 0.938 -3.38 1.56 0.033
FACT-G
    Concomitant diseasec -2.82 1.29 0.031 -3.89 1.21 0.002 -1.80 1.41 0.203
    Anxietyb -12.78 4.15 0.003 -9.35 4.02 0.022 -3.54 4.65 0.448
    Depressionb -8.78 3.32 0.009 -8.76 3.17 0.007 -10.28 3.58 0.005
    Positive lymphnode involvement 2.92 1.30 0.027 0.60 1.25 0.635 3.35 1.40 0.019
    Adjuvant intravenous chemotherapy -5.69 1.60 0.001 -0.98 1.59 0.540 -4.78 1.68 0.005
    Married or with a partnera 2.02 1.35 0.138 1.50 1.30 0.251 3.06 1.53 0.048
Factors found to be statistically significant in a multiple regression model are listed.
Parameter estimates that are bolded were statistically significant
a: Conditions at baseline (one month after surgery)
b: Scores for the Hospital Anxiety and Depression Scale (HADS) at baseline (one month after surgery)
c: Concomitant disease including hypertension, hyperlipidemia and diabetes at baseline (one month after surgery)
6 months 1 year 2 years
